Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma

Trial Profile

Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Venetoclax (Primary) ; Ibrutinib
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 24 Oct 2017 Status changed from suspended to recruiting.
    • 16 Mar 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top